Journal News

Finding novel drug targets
in tuberculosis

Editor’s note: Today is World Tuberculosis Day.
Jodie Johnston
By Jodie Johnston
March 24, 2020

Even 27 years since the World Health Organization declared the “white plague” a global emergency, about 1.5 million people still die from tuberculosis each year. It is estimated that around one-fourth of the world’s population is infected with this bacterial pathogen. While many cases are latent, tuberculosis can complicate other health conditions, such as HIV and diabetes, which also complicate tuberculosis treatment. Preliminary data from a small study, not yet peer reviewed, suggest that TB may also increase patients’ susceptibility to COVID-19.

The cover figure depicts the feedback inhibition of menaquinone biosynthesis by the downstream metabolite DHNA. DHNA, the last cytosolic metabolite in the menaquinone biosynthesis pathway prior to conversion to menaquinone in the membrane is shown inhibiting the reaction catalyzed by the Mtb–MenD tetramer (shown as a surface rendered structure). All compounds are shown as white sticks.

Our research team, based in New Zealand and funded by the Royal Society of New Zealand’s Marsden Fund, recently reported a novel mechanism of controlling synthesis of the essential vitamin K2 in the bacterial pathogen that causes tuberculosis. Our study was chosen as an Editors’ Pick by the Journal of Biological Chemistry.

We found that an enzyme called MenD from an early step in the process of making vitamin K2 is controlled by one of the metabolites produced at a later step, just before the vitamin K2 molecule is completed. Too much or too little vitamin K2 is toxic to the bacterium; this feedback inhibition allows the pathogen to slow down or speed up production of the vitamin.  

As far as we know, this is the first time that allosteric regulation has been reported for the menaquinone (vitamin K2) biosynthesis pathway in any domain of life.

The ability to control vitamin K2 levels is likely to help the pathogen to adapt to the changing, sometimes hostile, environment in the human host during infection. Since humans do not produce vitamin K2, the enzymes that work together to produce it in bacteria may represent targets for new antimicrobials. Our discovery of this regulation site and its structure provide a potential new target for selective drugs.

Our team includes three midcareer researchers with young families, all affiliated with the Maurice Wilkins Centre for Molecular Biodiscovery. With colleagues Ghader Bashiri and Esther Bulloch from the University of Auckland, my laboratory at the University of Canterbury plans to work to unravel more mysteries about microbial pathogens. With support from the Canterbury Medical Research Foundation and the Maurice Wilkins Centre, my lab is already tackling work on metabolic pathways in the bacteria Staphylococcus aureus, which causes a difficult-to-treat infection in healthcare settings.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Jodie Johnston
Jodie Johnston

Jodie Johnston is a senior lecturer in the School of Physical and Chemical Sciences and Biomolecular Interaction Centre at the University of Canterbury.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

CRISPR epigenome editor offers potential gene therapies
News

CRISPR epigenome editor offers potential gene therapies

April 25, 2025

Scientists from the University of California, Berkeley, created a system to modify the methylation patterns in neurons. They presented their findings at ASBMB 2025.

Finding a symphony among complex molecules
Profile

Finding a symphony among complex molecules

April 23, 2025

MOSAIC scholar Stanna Dorn uses total synthesis to recreate rare bacterial natural products with potential therapeutic applications.

E-cigarettes drive irreversible lung damage via free radicals
Journal News

E-cigarettes drive irreversible lung damage via free radicals

April 17, 2025

E-cigarettes are often thought to be safer because they lack many of the carcinogens found in tobacco cigarettes. However, scientists recently found that exposure to e-cigarette vapor can cause severe, irreversible lung damage.

Using DNA barcodes to capture local biodiversity
ASBMB Annual Meeting

Using DNA barcodes to capture local biodiversity

April 15, 2025

Undergraduate at the University of California, Santa Barbara, leads citizen science initiative to engage the public in DNA barcoding to catalog local biodiversity, fostering community involvement in science.

Targeting Toxoplasma parasites and their protein accomplices
Journal News

Targeting Toxoplasma parasites and their protein accomplices

April 11, 2025

Researchers identify that a Toxoplasma gondii enzyme drives parasite's survival. Read more about this recent study from the Journal of Lipid Research.

Scavenger protein receptor aids the transport of lipoproteins
Journal News

Scavenger protein receptor aids the transport of lipoproteins

April 11, 2025

Scientists elucidated how two major splice variants of scavenger receptors affect cellular localization in endothelial cells. Read more about this recent study from the Journal of Lipid Research.